Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is a clinical-stage company, which inherently carries some risk due to its limited patient data. However, with the potential for new clinical data to be released later this year, there is a chance for the safety and efficacy of PBFT02 to be demonstrated, which could significantly increase market confidence and drive stock growth. Despite the inherent risk in being a clinical-stage company, Passage Bio has a strong pipeline focused on addressing critical underlying pathologies in neurodegenerative diseases, giving confidence in the company's long-term potential. Additionally, its single reportable segment allows for focused development and efficient use of resources, potentially boosting profitability in the future.

Bears say

Passage Bio is a clinical-stage biotechnology company with a single segment focused on developing and advancing genetic medicines for neurodegenerative diseases. However, their recent regulatory update requiring a randomized controlled registrational study for PBFT02 has created significant challenges and uncertainties for the company. As a result, the removal of PBFT02 from our valuation, conservative business projections, and regulatory risks have led us to downgrade PASG to Neutral with a 12-month PT of $23, reflecting a 66% downside potential.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.